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Abstract. Histone deacetylase (HDAC) inhibitors have been 
shown to enhance radiation response in various cancer cell 
lines. Valproic acid (VPA) has been used in clinical practice for 
the treatment of epilepsy and other seizure disorders and is also 
one of the most represented HDAC inhibitors. The aim of this 
study was to evaluate the radiosensitizing ability of VPA and 
its mechanisms in four esophageal squamous cell carcinoma 
(ESCC) cell lines (TE9, TE10, TE11 and TE14). VPA inhibited 
the viability of all ESCC cells in a dose-dependent manner. The 
50% inhibitory concentration (IC50) value of VPA in each cell 
line was between 1.02-2.15 mM, which is higher than clinically 
used safe concentrations. VPA induced the hyperacetylation of 
histones H3 and H4, as well as apoptosis and had a radiosensi-
tizing effect on all four ESCC cell lines at a concentration of 
0.5 mM which is equivalent to the therapeutic plasma concentra-
tion of anti-epilepsy therapy in humans. The radiosensitization 
was accompanied by an increase in γH2AX levels, indicating 
the presence of double-strand breaks (DSBs), and decrease in 
Rad51 expression, a DSB repair protein. These results suggest 
that a clinically safe dose of VPA can enhance radiation-induced 
cytotoxicity in human ESCC cells by chromatin decondensation 
with histone hyperacetylation and downregulation of Rad51. In 
conclusion, VPA appears to be a safe and promising radiosensi-
tizer for esophageal cancer radiotherapy.
Introduction
Although esophageal cancer is a relatively uncommon disease, it 
is one of the deadliest cancers with an average five-year survival 
rate of approximately 17% (1). Curative treatment is offered in the 
absence of tumor invasion to other organs or distant metastases. 
In Japan, surgery is the standard therapy for patients with resect-
able disease. However, radiotherapy alone has been indicated 
in unresectable or medically inoperable patients as definitive 
or palliative treatment. Following the report by an intergroup 
randomized controlled trial (Radiation Therapy Oncology 
Group 85-01), which compared chemoradiotherapy (CRT) with 
radiotherapy alone, the combined modality treatment became a 
standard treatment for patients who received non-surgical treat-
ment for esophageal cancer (2,3). CRT is currently recognized 
as the standard therapeutic strategy for unresectable esophageal 
cancer with locally advanced tumor or distant lymph node 
metastasis (4,5). The combination of 5-fluorouracil (5-FU) and 
cisplatin (CDDP) together with radiation, has become the stan-
dard treatment, due to the synergism between the two agents and 
their radiosensitizing effects (6-8). However, these drugs also 
cause severe toxicity, for example, leukocytopenia, pulmonary 
dysfunction, pericardial effusion, pleural effusion, radiation 
pneumonitis, perforation and stenosis (4,9,10). Moreover, irradia-
tion enhances the risk of salvage surgery (11). New strategies to 
enhance local control and reduce side-effects in performing CRT 
are required. Various radiosensitizers including new anti-cancer 
drugs are currently being tested.
Histone acetyltransferases (HATs) and histone deacetylases 
(HDACs) regulate the acetylation and deacetylation of histone 
(12,13). Moreover, HDAC is related to the deacetylation of 
chromatin histone proteins as well as non-histone proteins, 
which regulate cell differentiation, apoptosis and growth arrest 
(14). At least 18 human HDACs (HDAC 1-11 and sirtuins 1-7) 
with varying functions, localizations and substrates have been 
identified (15). Aberrant HDAC activity has been observed in 
many human cancers (16). In esophageal squamous cell carci-
noma (ESCC), histone H4 has been shown to be significantly 
hyperacetylated in the early stage of cancer invasion and both 
the hyperacetylation of histone H4 and the high expression of 
HDAC1 have been shown to topologically co-localize in the 
same tumor (17). Silencing the increased expression of HDAC1 
by RNAi increases apoptosis and enhances the radiosensitivity 
of esophageal cancer cells (18). HDACs have been considered 
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as one of the most promising therapeutic targets for malig-
nant disease. Numerous studies have reported the antitumor 
efficacy of HDAC inhibitors. The HDAC inhibitor, vorinostat 
(SAHA, Zolinza®), was approved by the US Food and Drug 
Administration only for treating refractory cutaneous T cell 
lymphoma (19). Diverse HDAC inhibitors have entered clinical 
trials for a number of malignancies, differing in potency and 
enzyme specificity.
Valproic acid (VPA) is a well-known HDAC inhibitor as well 
as an anti-convulsant and it is safely used in the treatment of 
epilepsy and other seizure disorders. It has been reported that 
VPA enhances radiosensitivity in various cancer cell lines in vivo 
and in vitro (20-27). VPA offers considerable promise as a thera-
peutic agent for esophageal cancer. However, the radiosensitizing 
effect of VPA in esophageal cancer has not been confirmed. In 
the present study, the antitumor and radiosensitizing effects of 
VPA and its mechanisms were investigated in ESCC cell lines.
Materials and methods
Cell lines and treatment. Four human ESCC cell lines (TE9, 
poorly differentiated; TE10, highly differentiated; TE11, moder-
ately differentiated; and TE14, moderately differentiated) were 
kindly provided by Dr Tetsuro Nishihira (Kenotokorozawa 
Hospital, Saitama, Japan). Each cell line was cultured in RPMI-
1640 (Invitrogen, Japan) supplemented with 10% heat-inactivated 
fetal bovine serum (Nissui Pharmaceutical Co. Ltd., Japan), 
100 IU/ml penicillin, 100 µg/ml streptomycin (Invitrogen), 
2 mM glutamine (Nissui Pharmaceutical Co. Ltd.), and 0.5 mM 
sodium pyruvate at 37˚C in a humidified atmosphere of 5% 
CO2 in air. VPA (Sigma-Aldrich Co., Japan) was dissolved in 
phosphate-buffered saline (PBS) to a stock concentration of 
100 mM and stored at -20˚C. Cultures were irradiated using 
MBR-1520R-3 (Hitachi Medicotechnology, Hitachi, Japan) at 
a dose rate of 1 Gy/min. Power output of X-ray-irradiation was 
125 KV, 20 mA. Forward-scattered radiation, 0.5 mm Al and 
0.2 mm Cu filters were used.
Cell growth assay. The viability of cells treated with VPA was 
determined by a standard 3-(4,5-dimethylthiazol-2-yl)-2,5-di-
phenyltetrazolium bromide (MTT) assay. Each cell line was 
treated with VPA at various concentrations (0.01-5 mM) for 
72 h. The percentage inhibition was determined by comparing 
the cell density of the drug-treated cells with that of untreated 
controls. All experiments were repeated at least three times.
Clonogenic assay. The cells were plated into dishes and allowed 
to attach for 6 h. The medium was then replaced by medium with 
or without VPA. Following incubation for 24 h, the cells were 
irradiated at various doses (2-6 Gy). The cells were harvested 
by trypsinization, counted, and known concentrations of cells 
were re-plated into 100-mm culture dishes and returned to the 
incubator. After incubation for 7-10 days, the cell colonies were 
fixed and stained with 0.1% crystal violet. Colonies of >50 cells 
were manually counted to determine survival.
Western blotting. The cell lysates were prepared in denaturing 
SDS sample buffer and subjected to SDS-PAGE. Protein 
(20 µg) from each sample was loaded onto a 5-20% gradient 
polyacrylamide gel (e-PAGEL, Atto Co. Ltd., Japan). Proteins 
were transferred to PVDF membranes (Bio-Rad Laboratories, 
Hercules, CA, USA) and blocked with commercial gradient 
buffer (EzBlock, Atto Co. Ltd.) at room temperature for 30 min. 
The membrane was incubated with the primary antibody 
overnight. To assess the acetylation of histones, anti-acetyl-
histone H3 (Lys 14) (Millipore, Billerica, MA, USA) and 
anti-acetyl-histone H4 (Lys 12) (Millipore) were used as primary 
antibodies. β-actin antibody (Sigma) was used as the internal 
control. Anti-phospho-histone H2AX (Ser 139) antibody (Cell 
signaling Technology, Beverly, MA, USA) was used for the 
detection of DNA double-strand breaks (DSBs). Anti-Ku70, 
anti-Ku80 (Cell signaling Technology), anti-Rad51 (Millipore), 
and anti-DNA-PKcs antibody (Santa Cruz Biotechnology Inc., 
Santa Cruz, CA, USA) were used for the detection of DSB 
repair-related proteins. The immunoblots were visualized using 
an ECL Plus kit (GE Healthcare Japan Co. Ltd.). Antibody-
antigen complexes were detected using an ECL western blotting 
detection kit (GE Healthcare) and the Light Capture system 
(Atto Co. Ltd.). Quantification was performed with the CS 
analyzer program (Atto Co. Ltd.).
Immunofluorescent cytochemistry. Cells were cultured on 
Lab-Tec chamber slides (Nalge Nunc International, New York, 
NY, USA). The cells were then treated with VPA for designated 
times and irradiated. They were fixed in a mixture of methanol 
and acetone (1:1) for 15 min. The slides were immersed in 
methanol containing 0.3% H2O2 for 30 min, blocked with 3.3% 
normal goat serum in PBS, and incubated with anti-phospho-
histone H2AX (Ser 139) (Cell signaling Technology) and the 
anti-Rad51 antibody (Millipore) at 4˚C overnight. After sections 
were washed in PBS, the immunoreactivity was visualized by 
incubating the sections with anti-rabbit IgG antibody conjugated 
with Alexa Flour 488 or 594 (Molecular Probes, Eugene, OR, 
USA) for 1 h at room temperature. The slides were examined 
with an Olympus immunofluorescence microscope (BX50/
BX-FLA, Tokyo, Japan).
Assessment of apoptosis. Annexin V binding assay was used 
to assess phosphatidylserine externalization as a marker 
of apoptosis using the Pacific Blue™ Annexin V⁄SYTOX® 
AADvanced™ Apoptosis kit according to the manufacturer's 
instructions (Invitrogen). The extent of apoptosis was quantified 
by flow cytometry.
Statistical analysis. The results are expressed as the means ± SE. 
A Student's unpaired t-test was used for comparisons between 
unpaired groups. The 50% inhibitory concentration (IC50) was 
assessed by using non-linear regression to fit dose-response 
curves. A difference was regarded as significant if P<0.05. 
Prism 5 software (MDF Co. Ltd, Japan) was used for all the 
analyses.
Results
Anti-tumor efficacy of VPA. The effect of VPA on viability of 
the four ESCC cell lines was assessed by the MTT assay. Cells 
were treated with various concentrations of VPA for 72 h. VPA 
inhibited the viability of all ESCC cells in a dose dependent 
manner (Fig. 1). The IC50 value of VPA in each cell line was 
between 1.02-2.15 mM (Table Ⅰ).
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Inhibitory effect of VPA on HDAC. The expressions of acetylated 
histones H3 and H4 detected by western blotting were used to 
examine the inhibitory effect of VPA. First, each cell line was 
exposed to various concentrations of VPA (0.1-1.0 mM). VPA 
concentrations higher than 0.5 mM enhanced the hyperacety-
lation of histones H3 and H4 in all ESCC cell lines (Fig. 2A). 
The cells were then exposed to 0.5 mM VPA for various times 
(12-48 h). VPA increased histone hyperacetylation after the 
exposure of cells for >24 h (Fig. 2B).
Radiosensitizing effect of VPA. The radiosensitizing effect of 
VPA was assessed using a clonogenic assay. Since 0.5 mM VPA 
showed histone hyperacetylation, it was also used in combina-
tion with irradiation. VPA enhanced radiosensitivity in all 
ESCC cell lines (Fig. 3).
Irradiation-induced apoptosis enhanced by VPA. The apoptotic 
response to irradiation alone or the combination of irradiation 
and VPA was assessed. Cells were first cultured with or without 
0.5 mM VPA for 24 h, irradiated (6 Gy), and returned to culture 
for 48 h. The cells were then examined for the detection of 
apoptosis. VPA significantly increased the proportion of early 
apoptotic cells represented by Annexin V+/SYTOX- after irra-
diation in all ESCC cell lines. The proportion of late apoptotic 
Figure 1. ESCC cell growth inhibition by VPA. Cell viability was assessed by 
MTT assay. Four cell lines (TE9, TE10, TE11 and TE14) were treated with the 
indicated doses of VPA (0.01-5 mM). Results represent the means of more than 
three independent experiments with standard errors.
Table Ⅰ. IC50 values of VPA on ESCC cell lines.





Figure 2. Histone acetylation status determined after exposure to VPA. 
(A) ESCC cell lines (TE9, TE10, TE11 and TE14) were exposed for 24 h to the 
designated doses (0.1-1.0 mM) of VPA. (B) Cells were exposed for designated 
times (12-48 h) to 0.5 mM VPA. After exposure to VPA, cells were collected 
and subjected to immunoblot analysis for assessment of acetylated histone H3 
and H4 expression. Each blot is representative of two or three independent 
experiments with β-actin used as the loading control.
Figure 3. The effect of VPA on ESCC cell radiosensitivity. (A) The survival of 
each cell line (TE9, TE10, TE11 and TE14) after radiation without VPA was 
measured by clonogenic assay. (B) Radiosensitization combined with 0.5 mM 
VPA was examined by clonogenic assay. Results represent the means of two or 
three independent experiments with standard errors.
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cells represented by Annexin V/SYTOX+ was also increased 
(Fig. 4).
VPA increases DNA DSBs. The expression of γH2AX was 
analyzed in order to assess DNA DSBs. When ionizing radia-
tion induces DNA DSBs, at the sites of DSBs the histone H2AX 
is rapidly phosphorylated and forms γH2AX. γH2AX was thus 
examined as an indicator of DNA DSBs. Western blotting 
and immunofluorescent cytochemistry were performed. Cells 
were exposed to either no treatment or 0.5 mM VPA followed 
by irradiation (6 Gy). After 2 h, proteins were extracted and 
examined by western blotting. Irradiation caused an increase 
in the expression of γH2AX. The addition of VPA elevated 
the expression of γH2AX in all ESCC cell lines (Fig. 5A). 
Immunofluorescent cytochemistry also showed that the cells 
treated with a combination of VPA with radiation had a signifi-
cantly higher expression of γH2AX compared to the controls 
(Fig. 5B).
VPA attenuates Rad51 expression after irradiation. The effect 
of VPA on the expression of proteins known to be related to the 
repair of radiation-induced DSBs (e.g., Ku70, Ku80, Rad51 and 
DNA-PKcs) was examined by western blotting and immunoflu-
orescent cytochemistry. Cells were pre-treated with or without 
0.5 mM VPA for 24 h, irradiated (6 Gy), and re-incubated. After 
4 h, proteins were collected. The addition of VPA downregu-
lated the expression of Rad51. The expression levels of Ku70, 
Ku80 and DNA-PKcs did not change (Fig. 6A). Similarly, 
immunofluorescent cytochemistry showed that Rad51 foci were 
decreased by 0.5 mM VPA (Fig. 6B).
Discussion
The results of this study show for the first time that VPA enhances 
radiosensitivity in ESCC cell lines. The effect of radiosensitizer 
was seen in various histological types. The increase in DSBs 
by chromatin modulation and the downregulation of Rad51, a 
DSB repair protein, were considered as molecular mechanisms 
enhancing radiation sensitivity. Furthermore, the VPA concen-
tration used as a radiosensitizer was at a low and clinically 
achievable dose. Thus, VPA as a HDAC inhibitor may provide 
an additional approach to radiotherapy for esophageal cancer.
Previous laboratory studies have reported HDAC inhibitors 
are effective as radiosensitizers in many types of malignancies. 
These studies show that VPA in vitro enhances radiosensitivity 
in malignant glioma (20,22), colorectal carcinoma (21), leukemia 
(23,24,26,27) and retinoblastoma cells (25). Moreover, a corre-
sponding enhancement of therapeutic efficacy in vivo was also 
reported when VPA was combined with irradiation (20,21). To 
our knowledge, there are currently four on-going phase I clinical 
trials assessing the combination of HDAC inhibitors and radio-
therapy: VPA with radiotherapy for pediatric glioma, VPA with 
radiotherapy for pediatric refractory solid and central nervous 
system (CNS) tumors, VPA or hydralazine with CRT for cervical 
cancer, and vorinostat with palliative radiotherapy (28-31).
VPA is a short-chain fatty acid and its chemical properties 
allow easy delivery to the organisms and cells. VPA is rapidly 
absorbed after oral administration. In the human brain, VPA 
affects the function of the neurotransmitter, GABA, through 
several pathways including the inhibition of GABA degrada-
tion, increased synthesis of GABA, and decreased GABA 
turnover. VPA is well known as an anti-convulsant and is safely 
used in the treatment of epilepsy and other seizure disorders. 
VPA is in general well-tolerated by patients. Neurological 
side-effects, such as sedation, dizziness and tremors, as well 
as mild gastrointestinal toxicities are usually evident early 
during treatment. The most serious adverse events are liver 
failure and teratogenicity. In treating epilepsy, the therapeutic 
plasma concentration ranges from 50-100 µg/ml, equivalent to 
0.3-0.6 mM (31,32). Our results showed that IC50 values of VPA 
against ESCC cell lines were 1.02-2.15 mM, which were higher 
than clinically safe concentrations. However, VPA enhanced 
the hyperacetylation of histones H3 and H4 in all ESCC cell 
lines at a low concentration (0.5 mM), which is equivalent to 
Figure 4. The effect of VPA on apoptosis after irradiation (IR) of ESCC cell lines. The cell lines (TE9, TE10, TE11 and TE14) were treated with or without 0.5 mM 
VPA for 24 h, irradiated or not, and incubated for 48 h. Annexin V binding assay was used to assess phosphatidylserine externalization as a marker of apoptosis 
using the Pacific Blue™ Annexin V⁄SYTOX® AADvanced™ Apoptosis kit. The extent of apoptosis was quantified by flow cytometry. (A) Representative cytogram 
of TE11. Early apoptotic populations were localized in the lower right quadrants. Late apoptotic or necrotic populations were found in the upper right quadrants. 
(B) The percentage of early or late apoptotic cells after irradiation in four ESCC cell lines. Results represent the means of two or three independent experiments 
with standard errors.
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the anti-epilepsy therapeutic plasma concentration in humans. 
Thus, it can be concluded that pharmacologically relevant 
levels of VPA can cause the acetylation of histones and lead 
to the relaxation of chromatin structure. In addition, a low 
concentration (0.5 mM) of VPA also induced apoptosis and had 
a radiosensitizing effect.
There are two principal mechanisms by which low concen-
trations of HDAC inhibitors can radiosensitize tumor cells. First, 
HDAC inhibitors acetylate histone chromatin enabling access to 
the chromatin structure. Decondensed chromatin by deacety-
lation is more likely to cause permanent damage. Harikrishnan 
et al (23) reported that heterochromatin is more resistant to 
radiation-induced DSBs than euchromatin, and that radiosen-
sitivity of HDAC inhibitors depends on histone modification. 
Secondly, HDAC inhibitors can suppress the endogenous DNA 
repair process. In mammalian cells, DSBs are repaired mostly 
by either homologous recombination (HR) or non-homologous 
end-joining (NHEJ). Several HDAC inhibitors including VPA 
can downregulate DNA repair proteins related to HR (Rad51) 
(33-35) and NHEJ (Ku70, Ku86 and DNA-PKcs) (21,34-40). 
Munchi et al (38) noted that sodium butylate suppresses Ku70, 
Ku86 and DNA-PKcs at mRNA and protein levels. Chinnaiyan 
et al (35) argued that SAHA suppresses Rad51 and DNA-PKcs 
at protein levels. In our study, a low dose of VPA suppressed the 
expression of the Rad51 protein in ESCC cell lines.
Mammalian cells show different levels of radioresistance 
during the course of the cell cycle. Cells in the G2/M phase are 
more radiosensitive than in the S phase (41). Flow cytometry 
was used to assess the effect on different phases of the cell cycle. 
There was no difference in the distribution of cell cycle phases 
between untreated control cells and pre-treated cells (data not 
shown). Therefore, the low concentration VPA was non-toxic 
and did not induce cell cycle arrest. Taken together, we suggest 
that a low concentration of VPA sensitizes ESCC cells to 
irradiation by the modulation of chromatin structure and the 
downregulation of Rad51, the DNA DSBs repair protein.
While it is known that tumor cell lines differ in their 
p53 status, all ESCC cell lines used in this study had mutant-
type p53 (42). Forty to sixty percent of patients with esophageal 
cancer have p53 abnormalities, even in early pre-cancerous 
lesions (43). Previous studies on the relation of p53 status and 
radiosensitization by HDAC inhibitors have not yielded consis-
tent results. Chen et al (44) reported that only wild-type p53 was 
radiosensitized by VPA in colorectal cancer cells in vitro and 
Figure 5. The effect of VPA on radiation-induced DNA DSBs. Phosphorylated histone H2AX (γ-H2AX) was used as an indicator of DNA DSBs. (A) ESCC cells 
were cultured with or without 0.5 mM VPA for 24 h, and irradiated (6 Gy). After 2 h, lysates were collected. The protein expression level of γ-H2AX was analyzed 
by western blotting. Each blot is representative of two or three independent experiments with β-actin used as the loading control. (B) Micrographs of γ-H2AX foci 
on TE11 cells were obtained 2 h after irradiation by immunofluorescent cytochemistry. 
Figure 6. The effect of VPA on radiation-induced DNA DSBs repair protein expression. (A) Cells were cultured with or without 0.5 mM VPA for 24 h, and irradiated 
(6 Gy). After 4 h, lysates were extracted. The expression of DSB repair-related proteins including Ku70, Ku80, Rad51 and DNA-PKcs was analyzed by western 
blotting. (B) Micrographs of Rad51 foci on TE11 cells were obtained 4 h after irradiation. VPA decreased the expression of Rad51, a radiation-induced DSB repair 
protein, after irradiation.
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in vivo. However, phenylbutyrate radiosensitized only mutant-
type p53 in vitro. Moreover, phenylbutyrate radiosensitized 
the knockdown of wild-type p53 in glioblastoma cell lines 
(45). Kim et al (46) showed that trichostatin A significantly 
radiosensitized various cell lines (adenocarcinoma of the colon, 
adenocarcinoma of the lung, squamous cell carcinoma of the 
head/neck and squamous cell carcinoma of the uterus). The 
effect was also clearer in wild-type p53 than in mutant-type p53. 
Flatmark et al (47) also showed that irrespective of p53 status, 
trichostatin A sensitized colorectal cancer cell lines. Our results 
showed the radiosensitization of ESCC cells with mutant-type 
p53. It is not clear how p53 status influences radiosensitization 
by HDAC inhibitors, nor how HDAC inhibitors radiosensitize 
cancer cells. Conceivably, treatment efficacy may depend on 
histological origin among cancer cells. A currently held idea 
proposes a classification according to isoform-selective HDAC 
inhibition in probing for biological functions. A novel isoform-
selective HDAC inhibitor will be useful in elucidating the 
mechanism of action and the development of therapeutic agents 
with minimal side-effects (48).
HDAC inhibitors can suppress the radiation-induced damage 
of normal tissue. HDAC inhibitors have been shown to suppress 
cutaneous radiation syndrome (49) and radiation-induced oral 
mucositis (50). This mechanism is related to the downregula-
tion of TGF-β and TNF-α and the reduction of oxidative stress. 
HDAC inhibitors together with radiotherapy can protect normal 
tissue fibrosis and reduce severe toxicity. Particularly, HDAC 
inhibitors may prevent fibrosis followed by stenosis in esopha-
geal cancer treatment.
In conclusion, HDAC inhibitors are promising anti-cancer 
drugs with multiple functions. However, higher doses of HDAC 
inhibitors have severe toxicities and are difficult to use clini-
cally. With respect to radiosensitization, HDAC inhibitors at low 
concentrations are effective depending on the cell type. VPA is 
a representative HDAC inhibitor and its safe use in humans has 
already been established. Our results show the potential useful-
ness of VPA in combination with radiotherapy for treating 
esophageal cancer.
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